Phase 1 proof-of-concept study of CLY-124 in Sickle Cell Disease expected in Q4 2026In vivo preclinical data assessing new compounds vs. standard of care in gold-standard, translatable myelofibrosis ...
Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration ...
FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a ...
See, despite the name, the Tribute isn’t just for show - the modifications are serving a purpose as well. Or, to put it in ...
Chiplets enable scalability but dramatically raise interconnect complexity and risk. Silicon-proven NoC technology is the key ...
Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks– ...
The EV2 is Kia’s smallest EV to date and likely to start at about €30,000. Kia EV2 debuts as a compact SUV - CompleteCar.ie ...
Bravery is a virtue we all have today! With the emotional Moon harmonizing with transformative Pluto in the early hours, ...
ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today confirmed positive results from its Phase 2 Alpestria-1 study of vonafexor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback